{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:32:16Z","timestamp":1786357936262,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:00:00Z","timestamp":1693612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:00:00Z","timestamp":1693612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R13AG071150"],"award-info":[{"award-number":["R13AG071150"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s12325-023-02637-4","type":"journal-article","created":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T03:26:12Z","timestamp":1693625172000},"page":"4695-4710","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group"],"prefix":"10.1007","volume":"40","author":[{"given":"Michelle L.","family":"Mauermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Litchy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Obici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2944-1673","authenticated-orcid":false,"given":"Isabelle","family":"Lousada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Amyloidosis Forum Working Group Participants","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Barbachano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Faller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Jawidzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Koontz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Kowalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarrit","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,2]]},"reference":[{"issue":"1","key":"2637_CR1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","volume":"324","author":"MA Gertz","year":"2020","unstructured":"Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA. 2020;324(1):79\u201389.","journal-title":"JAMA"},{"issue":"1","key":"2637_CR2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","volume":"4","author":"G Merlini","year":"2018","unstructured":"Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"2637_CR3","first-page":"472","volume":"94","author":"E Muchtar","year":"2019","unstructured":"Muchtar E, Gertz MA, Kyle RA, et al. A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing. Mayo Clin Proc. 2019;94(3):472\u201383.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"2637_CR4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41409-018-0284-4","volume":"54","author":"C Varga","year":"2019","unstructured":"Varga C, Comenzo RL. High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review. Bone Marrow Transplant. 2019;54(4):508\u201318.","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 4","key":"2637_CR5","first-page":"45","volume":"13","author":"R Lu","year":"2022","unstructured":"Lu R, Richards T. A focus on Waldenstrom macroglobulinemia and AL amyloidosis. J Adv Pract Oncol. 2022;13(Suppl 4):45\u201356.","journal-title":"J Adv Pract Oncol"},{"issue":"5","key":"2637_CR6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ajh.23413","volume":"88","author":"TV Kourelis","year":"2013","unstructured":"Kourelis TV, Gertz M, Zent C, et al. Systemic amyloidosis associated with chronic lymphocytic leukemia\/small lymphocytic lymphoma. Am J Hematol. 2013;88(5):375\u20138.","journal-title":"Am J Hematol"},{"key":"2637_CR7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1750-1172-7-54","volume":"7","author":"E Desport","year":"2012","unstructured":"Desport E, Bridoux F, Sirac C, et al. Al amyloidosis. Orphanet J Rare Dis. 2012;7:54.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"2637_CR8","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","volume":"32","author":"I Lousada","year":"2015","unstructured":"Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium. Adv Ther. 2015;32(10):920\u20138.","journal-title":"Adv Ther"},{"issue":"2","key":"2637_CR9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40271-017-0273-5","volume":"11","author":"KL McCausland","year":"2018","unstructured":"McCausland KL, White MK, Guthrie SD, et al. Light chain (AL) amyloidosis: the journey to diagnosis. Patient. 2018;11(2):207\u201316.","journal-title":"Patient"},{"issue":"4","key":"2637_CR10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/13506129.2015.1102131","volume":"22","author":"HM Lin","year":"2015","unstructured":"Lin HM, Seldin D, Hui AM, Berg D, Dietrich CN, Flood E. The patient\u2019s perspective on the symptom and everyday life impact of AL amyloidosis. Amyloid. 2015;22(4):244\u201351.","journal-title":"Amyloid"},{"key":"2637_CR11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1477-7525-10-154","volume":"10","author":"M Bayliss","year":"2012","unstructured":"Bayliss M, Rendas-Baum R, White MK, Maruish M, Bjorner J, Tunis SL. Health-related quality of life (HRQL) for individuals with self-reported chronic physical and\/or mental health conditions: panel survey of an adult sample in the United States. Health Qual Life Outcomes. 2012;10:154.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"2637_CR12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","volume":"273","author":"IB Wilson","year":"1995","unstructured":"Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273(1):59\u201365.","journal-title":"JAMA"},{"issue":"4","key":"2637_CR13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/ejh.13681","volume":"107","author":"S Oubari","year":"2021","unstructured":"Oubari S, Naser E, Papathanasiou M, et al. Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement. Eur J Haematol. 2021;107(4):449\u201357.","journal-title":"Eur J Haematol"},{"issue":"5","key":"2637_CR14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-021-00483-7","volume":"11","author":"M Hasib Sidiqi","year":"2021","unstructured":"Hasib Sidiqi M, Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021. Blood Cancer J. 2021;11(5):90.","journal-title":"Blood Cancer J"},{"issue":"1","key":"2637_CR15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s13023-020-01525-2","volume":"15","author":"I Lousada","year":"2020","unstructured":"Inaugural Amyloidosis Forum Panelists, Lousada I. The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis. Orphanet J Rare Dis. 2020;15(1):268.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2637_CR16","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009038","volume":"15","author":"MS Maurer","year":"2022","unstructured":"Maurer MS, Dunnmon P, Fontana M, et al. Proposed cardiac end points for clinical trials in immunoglobulin light chain amyloidosis: report from the Amyloidosis Forum Cardiac Working Group. Circ Heart Fail. 2022;15(6):e009038.","journal-title":"Circ Heart Fail"},{"key":"2637_CR17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/PROM.S399658","volume":"14","author":"AAWM Rizio","year":"2023","unstructured":"Rizio AAWM, D\u2019Souza A, Hsu K, et al. Health-related quality of life instruments for clinical trials in AL amyloidosis: report from the Amyloidosis Forum HRQOL Working Group. Patient Relat Outcome Meas. 2023;14:153\u201369.","journal-title":"Patient Relat Outcome Meas"},{"issue":"3","key":"2637_CR18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0002-9343(98)00037-0","volume":"104","author":"SV Rajkumar","year":"1998","unstructured":"Rajkumar SV, Gertz MA, Kyle RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med. 1998;104(3):232\u20137.","journal-title":"Am J Med"},{"issue":"5","key":"2637_CR19","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/mus.25563","volume":"56","author":"PJ Dyck","year":"2017","unstructured":"Dyck PJ, Kincaid JC, Dyck PJB, et al. Assessing mNIS+7Ionis and international neurologists\u2019 proficiency in a familial amyloidotic polyneuropathy trial. Muscle Nerve. 2017;56(5):901\u201311.","journal-title":"Muscle Nerve"},{"issue":"1\u20132","key":"2637_CR20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jns.2014.06.041","volume":"344","author":"N Suanprasert","year":"2014","unstructured":"Suanprasert N, Berk JL, Benson MD, et al. Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials. J Neurol Sci. 2014;344(1\u20132):121\u20138.","journal-title":"J Neurol Sci"},{"issue":"4","key":"2637_CR21","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/mus.27022","volume":"62","author":"PJB Dyck","year":"2020","unstructured":"Dyck PJB, Kincaid JC, Wiesman JF, et al. mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin-mediated amyloidosis. Muscle Nerve. 2020;62(4):502\u20138.","journal-title":"Muscle Nerve"},{"key":"2637_CR22","doi-asserted-by":"crossref","first-page":"116424","DOI":"10.1016\/j.jns.2019.116424","volume":"405","author":"PJB Dyck","year":"2019","unstructured":"Dyck PJB, Gonz\u00e1lez-Duarte A, Obici L, et al. Development of measures of polyneuropathy impairment in hATTR amyloidosis: from NIS to mNIS+7. J Neurol Sci. 2019;405:116424.","journal-title":"J Neurol Sci"},{"issue":"4","key":"2637_CR23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","volume":"76","author":"SI van Nes","year":"2011","unstructured":"van Nes SI, Vanhoutte EK, van Doorn PA, et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology. 2011;76(4):337\u201345.","journal-title":"Neurology"},{"issue":"23","key":"2637_CR24","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1212\/WNL.0000000000001044","volume":"83","author":"TH Draak","year":"2014","unstructured":"Draak TH, Vanhoutte EK, van Nes SI, et al. Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness. Neurology. 2014;83(23):2124\u201332.","journal-title":"Neurology"},{"issue":"3","key":"2637_CR25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/13506129.2020.1730790","volume":"27","author":"L Obici","year":"2020","unstructured":"Obici L, Berk JL, Gonz\u00e1lez-Duarte A, et al. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid. 2020;27(3):153\u201362.","journal-title":"Amyloid"},{"issue":"3","key":"2637_CR26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/dia.2005.7.497","volume":"7","author":"EJ Vinik","year":"2005","unstructured":"Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients\u2019 perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther. 2005;7(3):497\u2013508.","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"2637_CR27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/jns5.12059","volume":"19","author":"EJ Vinik","year":"2014","unstructured":"Vinik EJ, Vinik AI, Paulson JF, et al. Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2014;19(2):104\u201314.","journal-title":"J Peripher Nerv Syst"},{"issue":"8","key":"2637_CR28","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785\u201392.","journal-title":"Neurology"},{"issue":"4","key":"2637_CR29","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jns.12350","volume":"24","author":"M Kapoor","year":"2019","unstructured":"Kapoor M, Foiani M, Heslegrave A, et al. Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. J Peripher Nerv Syst. 2019;24(4):314\u20139.","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"2637_CR30","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1212\/WNL.0000000000011090","volume":"96","author":"S Ticau","year":"2021","unstructured":"Ticau S, Sridharan GV, Tsour S, et al. Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis. Neurology. 2021;96(3):e412\u201322.","journal-title":"Neurology"},{"issue":"1","key":"2637_CR31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/13506129.2020.1815696","volume":"28","author":"J Louwsma","year":"2021","unstructured":"Louwsma J, Brunger AF, Bijzet J, et al. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis. Amyloid. 2021;28(1):50\u20135.","journal-title":"Amyloid"},{"issue":"12","key":"2637_CR32","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.mayocp.2012.10.013","volume":"87","author":"DM Sletten","year":"2012","unstructured":"Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc. 2012;87(12):1196\u2013201.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2637_CR33","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00415-019-09602-8","volume":"267","author":"A Gonz\u00e1lez-Duarte","year":"2020","unstructured":"Gonz\u00e1lez-Duarte A, Berk JL, Quan D, et al. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. J Neurol. 2020;267(3):703\u201312.","journal-title":"J Neurol"},{"issue":"5","key":"2637_CR34","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.md.0000091183.93122.c7","volume":"82","author":"MA Park","year":"2003","unstructured":"Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore). 2003;82(5):291\u20138.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2637_CR35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol. 2005;79(4):319\u201328.","journal-title":"Am J Hematol"},{"issue":"sup1","key":"2637_CR36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/13506129.2019.1582486","volume":"26","author":"E Muchtar","year":"2019","unstructured":"Muchtar E, Dispenzieri A, Leung N, et al. Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. Amyloid. 2019;26(sup1):101\u20132.","journal-title":"Amyloid"},{"issue":"7","key":"2637_CR37","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/BF02232969","volume":"13","author":"T Gilat","year":"1968","unstructured":"Gilat T, Spiro HM. Amyloidosis and the gut. Am J Dig Dis. 1968;13(7):619\u201333.","journal-title":"Am J Dig Dis"},{"issue":"1","key":"2637_CR38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0016-5107(94)70008-7","volume":"40","author":"S Tada","year":"1994","unstructured":"Tada S, Iida M, Yao T, et al. Endoscopic features in amyloidosis of the small intestine: clinical and morphologic differences between chemical types of amyloid protein. Gastrointest Endosc. 1994;40(1):45\u201350.","journal-title":"Gastrointest Endosc"},{"key":"2637_CR39","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.amjmed.2022.01.008","volume":"135","author":"CDL Fritz","year":"2022","unstructured":"Fritz CDL, Blaney E. Evaluation and management strategies for GI involvement with amyloidosis. Am J Med. 2022;135:S20\u20133.","journal-title":"Am J Med"},{"key":"2637_CR40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1750-1172-9-61","volume":"9","author":"J Wixner","year":"2014","unstructured":"Wixner J, Mundayat R, Karayal ON, et al. THAOS: gastrointestinal manifestations of transthyretin amyloidosis\u2014common complications of a rare disease. Orphanet J Rare Dis. 2014;9:61.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2637_CR41","volume":"30","author":"T Yen","year":"2018","unstructured":"Yen T, Chen FW, Witteles RM, Liedtke M, Nguyen LA. Clinical implications of gastrointestinal symptoms in systemic amyloidosis. Neurogastroenterol Motil. 2018;30(4): e13229.","journal-title":"Neurogastroenterol Motil"},{"key":"2637_CR42","doi-asserted-by":"crossref","first-page":"S1657","DOI":"10.14309\/01.ajg.0000714668.19384.55","volume":"115","author":"L Obici","year":"2020","unstructured":"Obici L, Gonzalez-Duarte A, Waddington-Cruz M, et al. S3155 impact of patisiran, an RNAi therapeutic, on diarrhea symptoms in patients with hereditary transthyretin-mediated amyloidosis. Am J Gastroenterol. 2020;115:S1657.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"2637_CR43","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/ajg.2014.237","volume":"109","author":"BMR Spiegel","year":"2014","unstructured":"Spiegel BMR, Hays RD, Bolus R, et al. Development of the NIH patient-reported outcomes measurement information system (PROMIS) gastrointestinal symptom scales. Am J Gastroenterol. 2014;109(11):1804\u201314.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2637_CR44","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/s10620-017-4499-9","volume":"62","author":"D Khanna","year":"2017","unstructured":"Khanna D, Hays RD, Shreiner AB, et al. Responsiveness to change and minimally important differences of the patient-reported outcomes measurement information system gastrointestinal symptoms scales. Dig Dis Sci. 2017;62(5):1186\u201392.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"2637_CR45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"2637_CR46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/13506129.2010.543443","volume":"18","author":"V Loustaud-Ratti","year":"2011","unstructured":"Loustaud-Ratti V, Cypierre A, Rousseau A, et al. Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool. Amyloid. 2011;18(1):19\u201324.","journal-title":"Amyloid"},{"issue":"4","key":"2637_CR47","doi-asserted-by":"crossref","first-page":"437","DOI":"10.15403\/jgld.2014.1121.234.hamy","volume":"23","author":"S Srinivasan","year":"2014","unstructured":"Srinivasan S, Tan YQ, Teh HS, Lee PJ, Khoo RN. Primary hepatic amyloidosis presenting as nodular masses on the background of diffuse infiltration and extreme liver stiffness on MR elastography. J Gastrointest Liver Dis. 2014;23(4):437\u201340.","journal-title":"J Gastrointest Liver Dis"},{"issue":"8","key":"2637_CR48","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1007\/s00261-015-0519-4","volume":"40","author":"DS Trifanov","year":"2015","unstructured":"Trifanov DS, Dhyani M, Bledsoe JR, et al. Amyloidosis of the liver on shear wave elastography: case report and review of literature. Abdom Imaging. 2015;40(8):3078\u201383.","journal-title":"Abdom Imaging"},{"issue":"5","key":"2637_CR49","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3390\/jcm8050739","volume":"8","author":"SK Venkatesh","year":"2019","unstructured":"Venkatesh SK, Hoodeshenas S, Venkatesh SH, et al. Magnetic resonance elastography of liver in light chain amyloidosis. J Clin Med. 2019;8(5):739.","journal-title":"J Clin Med"},{"key":"2637_CR50","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100720","volume":"45","author":"C Varga","year":"2021","unstructured":"Varga C, Dorbala S, Lousada I, et al. The diagnostic challenges of cardiac amyloidosis: a practical approach to the two main types. Blood Rev. 2021;45:100720.","journal-title":"Blood Rev"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02637-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02637-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02637-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T21:06:54Z","timestamp":1697058414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02637-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,2]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2637"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02637-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,2]]},"assertion":[{"value":"10 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Michelle Mauermann: Research funding from IONIS, Alnylam, EIDOS, Editorial board of<i> Mayo Clinic Proceedings<\/i>, Book royalties from Oxford Publishing. John O. Clarke: Consultant with Alnylam, Pfizer. William Litchy: Contracts with IONIS, Alnylam, EIDOS. Laura Obici: Speaker fees from Alnylam, SOBI, Pfizer and Akcea. Isabelle Lousada: None. Morie Gertz: DSMB: AbbVie, Celgene, Advisory Board: Ionis, Consulting: Akcea, Alnylm, Prothena, Honoraria and consulting, i3Health educational materials, Honoraria: Research to Practice, Ambry Genetics, Amgen, Janssen, Celgene, Karyopharm, Pfizer (to institution), Sanofi, Stock Options: Aurora Bio.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}